MK-2214 Study:To slow changes due to Alzheimer's disease
The MK-2214 study by Merck is designed to evaluate if MK-2214, an investigational drug, can slow down changes in the brain linked to Alzheimer's disease in people at an early stage. MK-2214 is investigational and has not been approved by the FDA.
Study highlights
Key information about the MK-2214 study
- 50 to 85 years old
- Early Alzheimer's Disease
- Study partner (friend or family) available
- Infusion
- Study zone: Southern California + North Central Florida
Study goal and design
Limiting the spread of tau protein in early Alzheimer's disease
The MK-2214 study by Merck is designed to evaluate if MK-2214, an investigational drug, can slow down changes in the brain linked to Alzheimer's disease in people at an early stage. By limiting the spread of tau, researchers hope the treatment may slow down the progression of memory loss and other symptoms of the disease.
Study-related care and support
Comprehensive medical oversight and support
While contributing to research, participants receive:
- The possibility to receive the investigational study drug
- Regular brain scans and memory assessments
- Study visits with qualified medical professionals
All medical and travel costs related to the study are covered.
Volunteer journey
A structured research experience
Express your interest
Answer a questionnaire to check preliminary criteria.
Meet the study team
Complete a detailed brain and memory evaluation.
Begin treatment (or placebo)
Receive MK-2214 or placebo by Intravenous IV infusion every 4 weeks for up to 2 years.
Continue the study
Be monitored during follow-up visits, and get health check-ups to observe any changes in cognition.
Ready to get involved?Join the Merck study today.
Contribute to progress, support research, help others, and care for your health.